Join CBMTG | Print Page | Contact Us | Sign In
Upcoming Webinars

Non-Member Price: $90 + tax
Member Price: FREE

The University of British Columbia Division of Continuing Professional Development (UBC CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide study credits for continuing medical education for physicians. This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by UBC CPD. You may claim a maximum of 11.0 hours (credits are automatically calculated). Each physician should claim only those credits he/she actually spent in the activity.

Wednesday, October 17, 2018
12:00pm PT / 3:00pm ET
CME CREDIT HOURS: 1.0                       

Transplant for Hemoglobinopathies
Greg Guilcher, MD, FRCPC, FAAP

Dr. Guilcher is an associate professor of oncology and paediatrics at the University of Calgary. His clinical and research focus is hematopoietic cell transplantation (HCT) for non-malignant diseases. He also studies acute and late effects of oncologic and BMT therapies. He serves as the Vice Chair of the Board of Directors and Clinical Operations for the Sickle Transplant Alliance for Research and is the Chair Mentee of the HCT Late Effects Taskforce for the Children's Oncology Group. He is Program Director for Pediatric Hematology/Oncology at the University of Calgary, volunteers in several roles with the Royal College of Physicians and Surgeons of Canada and teaches regularly in Mbarara, Uganda.

Hemoglobinopathies are common blood disorders worldwide. With newborn screening programs and immigration from endemic regions, Canadian hematology clinics across the country are providing comprehensive care to more children, adolescents and adults with transfusion dependent thalassemias (TDT) and sickle cell disease (SCD) than ever before. While supportive care is improving and novel therapies are emerging, long-term complications of iron burden or sickling crises prompt patients, families and care providers to explore potential curative options. This presentation summarizes the evidence to date for the application of allogeneic hematopoietic cell transplantation (HCT) for these hemoglobinopathies, with an emphasis on standards of care, experimental options and future directions.

Learning Objectives:
1. Identify the rationale for HSCT as a curative therapy for sickle cell disease (SCD)
2. Review the historical myeloablative approaches to conditioning
3. Identify populations at high risk of complications with strategies to make HSCT safer and more accessible for these populations

Wednesday, November 7, 2018
9:00am PT /12:00pm ET

Is There a Role for Cannabinoids in Hematologic Malignancies and Transplant?
Paul Daeninck, MD, MSc, FRCPC

Learning Objectives:
1. Describe the basics of the endocannabinoid system and epidemiology of cannabis/cannabinoid use
2. List the indications and evidence for cannabinoids as part of a supportive therapy program for patients with malignancies and undergoing transplant
3. Discuss the cautions and contraindications for use of cannabis and cannabinoids

Wednesday, December 5, 2018
9:00am PT /12:00pm ET   
CME CREDIT HOURS: 1.0                       

Viral Complications of Stem Cell Transplant
Shariq Haider, MD, FRCPC, FACP, CCST(UK), DTMH(UK)

Learning Objectives:


This website is sponsored by an unrestricted educational grant from:

Follow CBMTG